Clinical Trial Update: Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD [Phase 2, Phase 3]

View source ↗

Summary

Pivotal Phase 2/3 study of ABBV-RGX-314 (RGX-314) gene therapy for neovascular age-related macular degeneration evaluates subretinal delivery given as a one-tim…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Neovascular Age-related Macular Degeneration
• Wet Age-related Macular Degeneration

Drugs mentioned

• ABBV-RGX-314 (RGX-314)

Snippet

Sponsor: AbbVie | Conditions: AMD, nAMD | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING